Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT05569811
Title NeoadjuVAnt muLti-agENT Chemotherapy or Patritumab Deruxtecan With or Without endocrINE Therapy for High-risk HR+/HER2- Breast Cancer - VALENTINE Trial (VALENTINE)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors SOLTI Breast Cancer Research Group
Age Groups: senior | adult
Covered Countries ESP

No variant requirements are available.